Taysha Gene Therapies Total Long Term Liabilities 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Taysha Gene Therapies Total Long Term Liabilities 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$20.1B
Dr Reddy's Laboratories (RDY)	$13.1B
BridgeBio Pharma (BBIO)	$5B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.8B
Personalis (PSNL)	$315M
Assembly Biosciences (ASMB)	$117M
Acasti Pharma (ACST)	$28M
Sol-Gel Technologies (SLGL)	$20M
Evoke Pharma (EVOK)	$4M
Teligent (TLGT)	$0M